R. Von Moos - Kantonsspital Graubünden

基本信息

浏览量：110

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 400 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Olaparib Not Cost-Effective As Maintenance Therapy for Platinum-Sensitive, BRCA1/2 Germline-Mutated Metastatic Pancreatic Cancer

Tarun Mehra,Judith E. Lupatsch, Thibaud Kossler,Konstantin Dedes,Alexander Reinhard Siebenhuner,Roger von Moos,Andreas Wicki,Matthias E. Schwenkglenks

PLoS ONEno. 4 (2024): e0301271-e0301271

引用0浏览0WOS引用

Abstract PS15-08: Final Overall Survival (OS) Analysis of the SAKK 21/12 Trial. CR1447 in HR+/HER2- Metastatic Breast Cancer and Androgen Receptor Positive Triple Negative Breast Cancer

Marcus Vetter,Holer Lisa,Karin Rothgiesser, Wolfgang Schönfeld,Salome Riniker,Roger von Moos, Andreas Torjan,Elena Kralidis,Manuela Rabaglio,Mathias K. Fehr,Andreas Müller,Beat Thürlimann

Cancer Researchno. 9_Supplement (2024): PS15-08

引用0浏览0引用

First-line Durvalumab in Patients with PD-L1 Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) with a Performance Status of 2 (PS2). Primary Analysis of the Multicenter, Single-Arm Phase II Trial SAKK 19/17

Michael Mark,Patrizia Froesch,Katrin Gysel,Sacha I. Rothschild,Alfredo Addeo,Christoph J. Ackermann,Sabrina Chiquet,Martina Schneider,Karin Ribi,Angela Fischer Maranta,Sara Bastian,Roger von Moos,Markus Joerger,Martin Frueh

EUROPEAN JOURNAL OF CANCER（2024）

引用0浏览0WOS引用

Identifying the Drivers of Overall Rating of Cancer Care: Insights from the Second Wave of the Swiss Cancer Patient Experiences Study

Vladimir Jolidon,Manuela Eicher,Isabelle Peytremann-Bridevaux,Stefan Aebi,Sandro Anchisi,Adrienne Bettini,Yves Chalandon,Pierre-Yves Dietrich,Michel A. Duchosal, Donat Durr,Solange Peters,Roger von Moos, Andreas Wicki,Chantal Arditi

CANCER (2024)

引用0浏览0WOS引用

Un Impact Important Sur La Pratique Des Médecins

Roger von Moos,Markus Borner,Arnaud Roth, Urs Stoffel,Andreas Wicki, Dominique Froidevaux

Bulletin des Médecins Suisses (2024)

引用0浏览0引用

Are Bone Targeted Agents Still Useful in Times of Immunotherapy? the SAKK 80/19 BTA Pilot Study

Michael Mark, Alfonso Rojas Mora,Thomas Winder,Anastasios Stathis,Andreas Jakob, Gisela Muller,Stefanie Hayoz,Patrick Reimann,Ulf Petrausch,Roger von Moos

BONE REPORTS (2024)

引用0浏览0WOS引用

Data from MRI and ≪sup>18</sup>fet-Pet Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial

Hans‐Georg Wirsching, Ulrich Roelcke,Jonathan Weller,Thomas Hundsberger,Andreas F. Hottinger,Roger von Moos,Francesca Caparrotti,Katrin Conen,Luca Remonda,Patrick Roth,Adrian F. Ochsenbein,Ghazaleh Tabatabai,Michael Weller

openalex

引用0浏览0引用

Real-world Outcomes of Patients (pts) with Malignant Solid Tumors Treated with Immune Checkpoint Inhibitors (ICI) in Relation to Smoking Status: the SAKK 80/19 SMOKER Study

T. El Saadany,U. Petrausch, A. R. Mora,C. Renner,T. Winder,M. Benda,P. Reimann, A. Jakob, A. C. Daza, G. Mueller,R. von Moos,M. Mark

Journal of Clinical Oncologyno. 16_suppl (2023): 6619-6619

引用0浏览0引用

Abstract P4-01-25: Safety Analysis after 11 Years of Follow-Up of the Randomized Phase III Trial SAKK22/99: Upfront Chemotherapy in Advanced HER2 Positive Breast Cancer

Manuela Rabaglio,Daniel Dietrich,Bernhard Scheibe,Thomas Ruhstaller,Franco Nole,Serenella Eppenberger,Christian Oehlschlegel,Dagmar Hess,Christoph Mamot,Elisabetta Munzone,Bernhard Pestalozzi,Stefan Aebi,Marcus Vetter,Beat Thuerlimann,Roger von Moos,Khalil Zaman,Olivia Pagani

Cancer researchno. 5_Supplement (2023): P4-25

引用0浏览0引用

Safety Analysis after 11 Years of Follow-Up of the Randomized Phase III Trial SAKK22/99: Upfront Chemotherapy in Advanced HER2 Positive Breast Cancer

CANCER RESEARCHno. 5 (2023)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn